Changer d’antidépresseur : quand, comment, pourquoi ?

Gourion, David; Galinowski, A.; Baraille, L.; Picard, Hernàn

doi:10.1016/j.encep.2010.06.008

Cited by 3 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, such a restrictive inclusion criterion may have contributed to the exclusion of some patients over the follow-up period, given the frequent occurrence of therapeutic modifications. 39 In fact, in relation to other possible drop-out contributors, additional analysis of follow-up completers versus drop-outs did not show any statistical difference that might be interpreted as responsible for the high drop-out rate. Finally, a possible interaction with concomitant pharmacological treatments, in both acute phase and follow-up, might have influenced the results.…”

Section: Discussionmentioning

confidence: 81%

Augmentative transcranial direct current stimulation (tDCS) in poor responder depressed patients: a follow-up study

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 81%

Augmentative transcranial direct current stimulation (tDCS) in poor responder depressed patients: a follow-up study

et al. 2013

View full text Add to dashboard Cite

show abstract

“…One option after non-response to a first-line agent is switching to a different antidepressant, a strategy associated with response rates between 17 % and 70 % in double-blind and open-label studies [4,5]. Further treatment options are augmentation treatment, especially with lithium, repetitive transcranial stimulation (rTMS), and electro-convulsive treatment (ECT).…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Medical Cannabis for the Treatment of Depression: A Naturalistic Outpatient Study

Specka,

Bonnet,

Schmidberg

et al. 2024

Pharmacopsychiatry

View full text Add to dashboard Cite

Background There is a lack of studies on the course and effectiveness of medical cannabis in the treatment of major depressive disorder (MDD). Methods Retrospective longitudinal (18 weeks) study of n=59 outpatients with MDD, treated with medical cannabis via a telemedical platform. Previous treatment with antidepressant medication was required for inclusion into the study. Standardized data collection was carried out at entry and during monthly consultations. Severity of depression was measured on a 0–10 point rating scale. Side-effects were assessed by a checklist. Results Patients were 20–54 years old; 72.9% were male; one third reported times of regular cannabis consumption within the previous five years. Drop-out rate was 22% after 18 weeks. Mean severity of depression decreased from 6.9 points (SD 1.5) at entry to 3.8 points (2.7) at week 18 (baseline observation carried forward; 95% CI for the mean difference: 2.4 to 3.8; p<0.001). A treatment response (>50% reduction of the initial score) was seen in 50.8% at week 18. One third of patients complained about side effects, none was considered as severe. Concomitant antidepressant medication (31% of patients) was not associated with outcome. Conclusions Medical cannabis was well tolerated and dropout rate was comparable to those in clinical trials of antidepressant medication. Patients reported a clinically significant reduction of depression severity. Further research on the effectiveness of medical cannabis for MDD seems warranted. Risks of this medication, such as sustaining or inducing a cannabis use disorder, or side effects such as poor concentration, must be taken into consideration.

show abstract

Prescriptions séquentielles : arguments en faveur d’une modification des schémas thérapeutiques dans les dépressions résistantes

Allouche

2016

L'Encéphale

View full text Add to dashboard Cite

Changer d’antidépresseur : quand, comment, pourquoi ?

Cited by 3 publications

References 43 publications

Augmentative transcranial direct current stimulation (tDCS) in poor responder depressed patients: a follow-up study

Augmentative transcranial direct current stimulation (tDCS) in poor responder depressed patients: a follow-up study

Effectiveness of Medical Cannabis for the Treatment of Depression: A Naturalistic Outpatient Study

Prescriptions séquentielles : arguments en faveur d’une modification des schémas thérapeutiques dans les dépressions résistantes

Contact Info

Product

Resources

About